Clinical Trials: Multiple Sclerosis

Birmingham : Alabama Neurology Associates

A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis

Birmingham : Tanner Center and Foundation for MS

Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire

Birmingham : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Cullman : Investigational Site Number 840049 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Cullman : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

View More »

Cullman : Investigational Site Number 8965 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Cullman : North Central Neurology Associates PC

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Cullman : Teva Investigational Site 10192 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Cordova : Investigational Site Number 840005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Phoenix : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Phoenix : St. Joseph’s Hospital and Medical Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Tucson : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

View More »

Phoenix : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Phoenix : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Phoenix : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Phoenix : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Phoenix : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Phoenix : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Phoenix : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Phoenix : Investigational Site Number 840052 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Phoenix : St. Joseph's Hospital Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Scottsdale : Neuromuscular Research Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Tempe : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Tucson : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tucson : Northwest NeuroSpecialists, PLLC

A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis

Tucson : Northwest NeuroSpecialists, PLLC

A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

Tucson : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tucson : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Tucson : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Tucson : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Little Rock : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Berkeley : Jordan Research and Education Institute

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Los Angeles : University of Southern California - Keck School of Medicine

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Aliso Viejo : Avanir Pharmaceuticals

PRISM Registry: Pseudobulbar Affect Registry Series

Berkeley : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Berkeley : Alta Bates Summit Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Fresno : Victoria Walton, MD

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Fresno : Teva Investigational Site 10204 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Fullerton : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Fullerton : Fullerton Neurology and Headache Center

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Fullteron : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Garden Grove : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

La Jolla : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

La Jolla : Coordinated Clinical Research

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Los Angeles : USC MS Comprehensive Care Center

Clinical 15 Months Study Comparing Monthly Pulse ACTH (Acthar Gel) Therapy With Monthly Methylprednisolone (MP, Solumedrol) for Multiple Sclerosis (MS) Patients Who Are on Regular Beta-interferons (Avonex, Betaseron or Rebif)

Los Angeles : University of California Los Angeles

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Los Angeles : USC MS Comprehensive Care Center & Research Group

Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities

Los Angeles : USC

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Newport Beach : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Newport Beach : Investigational Site Number 840048 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Newport Beach : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Newport Beach : Multiple Sclerosis Center of Southern California & Research

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Oakland : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Oceanside : Neurology Center

Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire

Pasadena : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Sacramento : Sutter Institute for Medical Research

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

San Diego : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

San Diego : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

San Francisco : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

San Francisco : University of California, San Francisco

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

San Francisco : University of California San Francisco

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Temecula : Viking Clinical Research Center

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Torrance : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Valencia : Sanguine Biosciences

A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery

Centennial : 1st International Clinical Research Center

Do you have Relapsing Remitting Multiple Sclerosis?

Denver : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

View More »

Aurora : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Aurora : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Aurora : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Centennial : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Centennial : Teva Investigational Site 10196 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Denver : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Denver : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Englewood : Colorado Neurological Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Fort Collins : Investigational Site Number 840036 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Fort Collins : Investigational Site Number 8962 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Fort Collins : Advanced Neurosciences Research

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Ft. Collins : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Ft. Collins : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Ft. Collins : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

New London : Coastal Connecticut Research, LLC

Are You Currently Being Treated for a Relapsing Form of Multiple Sclerosis?

Pawcatuck : CNS Research of CT, Inc.

A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.

View More »

Fairfield : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Newark : Christiana Care Health Services

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Port Charlotte : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Sarasota : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

St. Petersburg : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Tampa : Axiom Clinical Research of Florida

A clinical research study for patients with Primary Progressive Multiple Sclerosis

Tampa : Axiom Clinical Research of Florida

A clinical research study for patients with Relapsing Remitting Multiple Sclerosis

Tampa : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

View More »

Bradenton : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Bradenton : Brandenton Neurology, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Hollywood : Infinity Clinical Research

Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire

Hollywood : Sunrise Clinical Research, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Jacksonville : University of Florida

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Maitland : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Maitland : Investigational Site Number 840012 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Maitland : Investigational Site Number 8920 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Maitland : Neurology Associates, PA

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Maitland : Neurology Associates, PA

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Melbourne : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Miami : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Miami : University of Miami

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Naples : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

North Palm Beach : Laszlo J. Mate, MD

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Orlando : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Orlando : McCare Center Neurology Services

Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire

Ormond Beach : Investigational Site Number 840013 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Ormond Beach : Neurology Associates of Ormond Beach

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Ormond Beach : Neurology Associates of Ormond Beach

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Pompano Beach : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Pompano Beach : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Pompano Beach : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Pompano Beach : Neurological Associates

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Pompano Beach : Neurological Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Port Charlotte : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Port Charlotte : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Port Orange : Progressive Medical Research

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Sarasota : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Sarasota : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Sarasota : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Sarasota : Investigational Site Number 840008 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Sarasota : Roskamp Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Sarasota : Teva Investigational Site 10180 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

South Miami : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

St. Petersburg : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

St. Petersburg : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

St. Petersburg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

St. Petersburg : Investigational Site Number 840021 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

St. Petersburg : Investigational Site Number 8953 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

St. Petersburg : Suncoast Neuroscience Associates, Inc.

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

St. Petersburg : Suncoast Neuroscience Associates, Inc

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Sunrise : Neurology Clinical Research

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Sunrise : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Tallahassee : AMO Corporation

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Tampa : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tampa : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Tampa : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Tampa : Investigational Site Number 840004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Tampa : Investigational Site Number 840047 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Tampa : University of South Florida

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Tampa : Teva Investigational Site 10190 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Tampa : Teva Investigational Site 10207 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Vero Beach : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Vero Beach : Geodyssey Research, LLC

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Vero Beach : MS Center of Vero Beach

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

West Palm Beach : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Weston : Cleveland Clinic Florida

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Atlanta : NeuroTrials Research

Living with Multiple Sclerosis? Enrolling for a 96-week, non-placebo, comparative trial.

Atlanta : Neurotrials Research, Inc.

Multiple Sclerosis

View More »

Atlanta : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Atlanta : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Atlanta : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Atlanta : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Atlanta : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Atlanta : Shepard Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Decatur : Neurostudies

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Honolulu : Leo Maher, MD

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Elk Grove Village : Alexian Brothers Hospital Network

A 6 month, randomized, active comparator, open-label, multi-center study to evaluate patient outcomes, safety and tolerability of Fingolimod (FTY720) 0.5mg/day in patients with relapsing remitting MS who are candidates for MS therapy change from previous disease modifying therapy (EPOC).

Flossmoor : South Suburban Neurology

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Barrington : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Champaign : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Chicago : Investigational Site Number 840034 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Chicago : University of Chicago

Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis

Elk Grove Village : Investigational Site Number 840037 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Evanston : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Flossmoor : South Suburban Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Lake Barrington : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Lake Barrington : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Lake Barrington : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Lake Barrington : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Northbrook : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Northbrook : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Northbrook : Consultants in Neurology

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Peoria : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Indianapolis : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

View More »

Avon : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Fort Wayne : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Ft. Wayne : Investigational Site Number 840025 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Ft. Wayne : Investigational Site Number 8914 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Indianapolis : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Indianapolis : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Indianapolis : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Indianapolis : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Indianapolis : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Indianapolis : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Indianapolis : Investigational Site Number 8940 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Indianapolis : Josephson Wallack Munshower Neurology, P.C.

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Merrillville : Neuroscience Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Des Moines : Ruan Neurology Research

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Des Moines : Mercy Ruan Neurology Clinic Res Ct.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Lenexa : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Lenexa : MidAmerica Neuroscience Institute

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Kansas City : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Kansas City : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Kansas City : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Lenexa : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Lenexa : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lenexa : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Lenexa : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Lenexa : MidAmerica Neuroscience Institute

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Lenexa : Mid America Neuroscience Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Overland Park : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Topeka : Precise Clinical Research

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Topeka : Cotton O'Neil Clinical Research Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Lexington : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Lexington : Associates in Neurology, P.S.C.

A Phase 3 study of PEGylated Interferon Beta-1a vs Placebo for subjects with Relapsing Remitting Multiple Sclerosis.

Lexington : Associates in Neurology, P.S.C.

A Phase 3 Study to determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon-beta-1a) in Patients with Relapsing-Remitting Multiple Sclerosis.

Lexington : Associates in Neurology, P.S.C.

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif) in patients with Relapsing Multiple Sclerosis.

Lexington : Associates in Neurology, P.S.C.

Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10mg twice daily) in Patients with Multiple Sclerosis. Sponsored by: Acorda Therapeutics.

Lexington : Associates in Neurology, P.S.C.

Multicenter, open-labeled, randomized, active comparator research study to evaluate patient outcome, safety and tolerability of an investigational medicine in patients with Relapsing forms of Multiple Sclerosis and who are candidates for MS therapy change from previous disease modifying therapy.

Lexington : Associates in Neurology, P.S.C.

This trial is evaluating the safety and efficacy of an investigational oral medication for the treatment of spasticity in patients with multiple sclerosis (MS).

View More »

Lexington : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Lexington : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Lexington : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Lexington : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Lexington : Associates in Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Louisville : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Louisville : Investigational Site Number 840033 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Louisville : University of Louisville (recruiting nationwide)

Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms

Louisville : Norton Healthcare, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Shreveport : Louisiana State University

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Shreveport : Investigational Site Number 8922 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Baltimore : University of Maryland

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Baltimore : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Baltimore : Investigational Site Number 840028 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Baltimore : University of Maryland

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Baltimore : Johns Hopkins University

Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis

Bethesda : Bethesda Neurology, LLC

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Bellingham : CNS Research of MA, Inc.

A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.

Boston : Brigham Women’s Hospital

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Boston : Caritas St. Elizabeth's Hospital

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Burlington : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Cambridge : Outcome Sciences, Inc

Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials

Milford : Milford Regional Medical Center

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Springfield : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Springfield : Springfield Neurology Associates, LLC

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Worcester : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Worcester : Fallon Clinic at Worcester Medical Center

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Worchester : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Bingham Farms : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Bingham Farms : QUEST Research Institute

Multiple Sclerosis Spasticity Study

View More »

Ann Arbor : Universitly of Michigan

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Bingham Farms : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Bingham Farms : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Clinton Township : Investigational Site Number 840016 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Clinton TWP : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Clinton Twp : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Clinton Twp : Michigan Neurology Associates, P.C.

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Detroit : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Detroit : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Detroit : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Detroit : Henry Ford Health System

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Farmington Hills : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Farmington Hills : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Farmington Hills : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Farmington Hills : Michigan Institute For Neurological Disorders

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Grand Rapids : Investigational Site Number 8955 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Traverse City : Investigational Site Number 8949 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Minneapolis : University of Minnesota

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Edina : Minneapolis Clinic of Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Hattiesburg : Hattiesburg Clinic Neurological Research Center

Study of the effect on cognitive performance, safety and tolerability of SAR110894D at doses of 0.5 mg, 2 mg and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy

Kansas City : Saint Luke's Hospital

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Saint Louis : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Springfield : St.John's Research Institute, Inc

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

St Louis : Investigational Site Number 840030 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

St Louis : Investigational Site Number 840031 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

View More »

St Louis : Investigational Site Number 8937 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

St. Louis : Washington University (John L. Trotter MS Center)

Ampyra for Optic Neuritis in MS

Great Falls : Advanced Neurology Specialists

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Great Falls : Benefis Physician Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Missoula : Investigational Site Number 840009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Lincoln : Neurology Associates PC

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Lebanon : Dartmouth Hitchcock Medical Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Lebanon : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Toms River : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

View More »

Freehold : CentraState Medical Center.

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Newark : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Newark : UMDNJ

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Teaneck : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Teaneck : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Toms River : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Toms River : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Albuquerque : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

View More »

Albuquerque : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Albuquerque : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Albuquerque : Investigational Site Number 840023 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Buffalo : Jacobs Neurological Institute Buffalo General Hospital

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Mineola : Winthrop University Hospital Clinical Trials Center

Multiple Sclerosis - (MS) Primary Progressive Multiple Sclerosis

New York : Judith Jaffe Multiple Sclerosis Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Patchogue : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Plainview : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

View More »

Albany : Upstate Clinical Research, LLC

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Albany : Neurological Associates of Albany, PC

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Amherst : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Buffalo : Research Site

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance

Buffalo : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Latham : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Latham : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Latham : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Latham : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Latham : Empire Neurology, PC

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

New York : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

New York : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

New York : Investigational Site Number 8925 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

New York : NYU-Hospital for Joint Diseases

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

New York : Mount Sinai School of Medicine

Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks

Patchogue : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Patchogue : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Patchogue : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Patchogue : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Patchogue : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Patchogue : South Shore Neurologic Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Plainview : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Plainview : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Plainview : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Plainview : Island Neurological Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Rochester : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Rochester : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Rochester : University of Rochester

Lubiprostone in Patients With Multiple Sclerosis Associated Constipation

Rochester : University of Rochester

Memantine for Spasticity in MS Patients

Rochester : University of Rochester

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Rochester : University of Rochester Medical Center

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Stony Brook : Stony Brook University

Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)

Stony Brook : SUNY at Stony Brook

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Asheville : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Chapel Hill : University of North Carolina

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Hickory : PMG Research of Hickory

Do you have Multiple Scerosis (MS)?

Hickory : PMG Research of Hickory

Do You Have Multiple Sclerosis (MS)?

Winston Salem : PMG Research of Winston-Salem

Have you been diagnosed with a relapsing form of Multiple Sclerosis?

View More »

Advance : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Advance : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Advance : Investigational Site Number 840039 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Advance : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Advance : Cornerstone Research Care

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Asheville : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Asheville : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Charlotte : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Charlotte : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Charlotte : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Charlotte : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Charlotte : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Charlotte : Investigational Site Number 840027 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Charlotte : Neuroscience and Spine Institute/MS Center

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Charlotte : Investigational Site Number 8941 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Charlotte : The Neurological Institute, PA

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Charlotte : Teva Investigational Site 10198 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Charlotte, : Carolinas Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Hickory : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Hickory : Teva Investigational Site 10203 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

High Point : Cornerstone Neurology

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

Raleigh : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Raleigh : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Winston Salem : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Winston-Salem : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Bismarck : Legacy Pharma Research

MS - Central Neuropathic Pain due to Multiple Sclerosis

Bismarck : Legacy Pharma Research

MS - Central Neuropathic Pain due to Multiple Sclerosis

View More »

Bismark : Investigational Site Number 840006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Fargo : Investigational Site Number 840007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Grand Forks : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Akron : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Akron : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Akron : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Akron : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Akron : Teva Investigational Site 10194 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

View More »

Cincinnati : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Cleveland : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Cleveland : Cleveland Clinic Foundation

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Columbus : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Dayton : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Dayton : Investigational Site Number 840046 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Dayton : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Dayton : Investigational Site Number 8924 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Dayton : Neurology Specialists, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Gahanna : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Toledo : Investigational Site Number 840017 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Uniontown : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Uniontown : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Uniontown : Teva Investigational Site 10200 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Oklahoma City : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Oklahoma City : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Oklahoma City : Oklahoma Medical Research Foundation

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Tulsa : Investigational Site Number 840043 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Portland : Providence St. Vincent Medical Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Corvallis : The Corvallis Clinic, P.C.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Medford : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Portland : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Portland : Oregon Health and Science University

Dalfampridine for Imbalance in Multiple Sclerosis

Portland : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Portland : Providence Multiple Sclerosis Center

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Abington : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Abinton : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Allentown : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Allentown : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Greensburg : Westmoreland Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

View More »

Philadelphia : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Philadelphia : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Philadelphia : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Philadelphia : Investigational Site Number 8956 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Philadelphia : University of Pennsylvania Health System

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Pittsburg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Pittsburgh : Research Protocol Management Solutions

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Providence : CNS Research of RI, Inc.

A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.

Providence : The Neurology Foundation, Inc.

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

View More »

Providence : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Providence : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Providence : Neurology Foundation

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Greenville : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Franklin : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Franklin : Advanced Neurosciences Institute

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Nashville : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

View More »

Franklin : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Franklin : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Franklin : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Franklin : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Franklin : Advanced Neurosciences Institute

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Knoxville : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Knoxville : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Memphis : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Memphis : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Nashville : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Nashville : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Nashville : Investigational Site Number 840002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Round Rock : Investigational Site Number 840040 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Round Rock : Investigational Site Number 8905 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

San Antonio : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

View More »

Dallas : Baylor Research Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Dallas : University of Texas Southwestern

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Dallas : UT Southwestern

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Houston : Baylor College of Medicine

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Lubbock : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Round Rock : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Round Rock : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Round Rock : Central Texas Neurology

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Round Rock : Central Texas Neurology Consultants, P.A.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

San Antonio : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

San Antonio : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

San Antonio : Investigational Site Number 840020 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

San Antonio : Innovative Clinical Trials, Bexar Diagnostic Medicine Assoc.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Sherman : Texoma Neurology Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Salt Lake City : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Salt Lake City : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Salt Lake City : Rocky Mountain MS Clinic

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Burlington : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Burlington : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Burlington : Investigational Site Number 8930 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Charlottesville : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Fairfax : Neurology Center of Fairfax

Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire

Newport New : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Norfolk : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Richmond : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

View More »

Vienna : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Vienna : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Vienna : Investigational Site Number 840032 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Vienna : MS Center of Greater Washington

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Seattle : Benaroya Research Institute at Virginia Mason

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Tacoma : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

View More »

Kirkland : MS Center at Evergreen

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

Kirkland : Evergreen Healthcare

A Study to Test the Use of Duloxetine for Pain in MS

Kirkland : MS Center at Evergreen Healthcare

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients With Multiple Sclerosis Taking Glatiramer Acetate

Kirkland : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Seattle : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Seattle : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Seattle : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Seattle : Investigational Site Number 8963 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Seattle : Swedish Medical Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Seattle : Swedish Neuroscience Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Seattle : Pacific Medical Centers

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Seattle : MS Hub

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Tacoma : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tacoma : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Tacoma : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Tacoma : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tacoma : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Tacoma : MultiCare Health System

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Tacoma : MultiCare Research Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Morgantown : United BioSource Corporation

Pregnancy Exposure Registry for Tysabri

Milwaukee : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Milwaukee : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Milwaukee : Aurora Health Care

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Argentina : Investigational Site Number 032002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Buenos Aires : Investigational Site Number 032003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Buenos Aires : Fundación Argentina Contra las Enfermedades Neurológicas del Envejecimiento - FACENE

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Caba : Investigational Site Number 032004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Ciudad Autonoma de Buenos Aires : Medeos - Centro de Medicina Integral e Investigación Clínica

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

View More »

Ciudad Autonoma de Buenos Aires : Instituto de Neurologia Cognitiva

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Ciudad Autónoma de Buenos Aires : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Ciudad de Buenos Aires : Instituto Argentino de Investigacion Neurologica

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Godoy Cruz : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Rosario : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Adelaide : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Auchenflower : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Ballarat : Investigational Site Number 036009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bedford Park : Investigational Site Number 036008 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bedford Park : Investigational Site Number 1408 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

View More »

Box Hill : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Bruce : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Chatswood : Investigational Site Number 036005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Chatswood : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Clayton : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Concord : Investigational Site Number 036003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Fitzroy : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Fitzroy : St Vincent's Hospital

Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis

Fitzroy : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Footscray : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Geelong : Investigational Site Number 1405 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Geelong : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Gold Coast : Investigational Site Number 1409 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Heidelberg : Investigational Site Number 1404 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Heidelberg : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Heidelberg West : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Heidelberg West : Investigational Site Number 036001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Hobart : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Hobart : Investigational Site Number 1407 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Kogarah : Investigational Site Number 036004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

New Lambton : Investigational Site Number 036010 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Orange : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Parkville : Investigational Site Number 1401 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Perth : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

St Leonards : Investigational Site Number 036002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Woollongong : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Graz : Investigational Site Number 040001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Innsbruck : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Innsbruck : Investigational Site Number 4004 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Linz : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Linz : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

View More »

Linz : Investigational Site Number 040004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Linz : Investigational Site Number 4005 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Linz : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations : Updated

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Salzburg : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Salzburg : Investigational Site Number 040003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Vienna : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Wien : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Wien : Investigational Site Number 040002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Wien : Investigational Site Number 4001 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Antwerpen : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Brabant Wallon : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Brasschaat : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Brugge : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bruxelles : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

View More »

Bruxelles : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Charleroi : Investigational Site Number 056005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Esneux : Centre Hospitalier Universitaire de Liège Ourthe Ambléve

Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction

Gent : Investigational Site Number 056004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Hainaut : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Hasselt : Investigational Site Number 056003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

La Louviere : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

La Louvière : Investigational Site Number 056006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Leuven : Investigational Site Number 056002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Leuven : UZ Gasthuisberg

Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction

Liege : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Liège : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Liège : Centre Hospitalier Universitaire de Liège

Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis

Limburg : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Luxembourg : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations : Updated

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Oost-Vlaanderen : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Sijsele-damme : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Sijsele-Damme : Investigational Site Number 056001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

West-Vlaanderen : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Wilrijk : Investigational Site Number 056007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Wilrijk : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Sarajevo : Teva Investigational Site 69001 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Tuzla : Teva Investigational Site 69003 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Belo Horizonte : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Brasilia : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Campinas : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Joinville : Investigational Site Number 076009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Passo Fundo : Investigational Site Number 076012 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

View More »

Porto Alegre : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Porto Alegre : Investigational Site Number 076003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Porto Alegre : Investigational Site Number 076005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Recife : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Recife : Investigational Site Number 076010 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Ribeirão Preto : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Rio de Janeiro : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Sao Paulo : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Sao Paulo : Investigational Site Number 076007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Pleven : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Pleven : Investigational Site Number 5312 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Plovdiv : Synthon investigational site 206

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Sofia : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

View More »

Sofia : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Sofia : Synthon investigational site 202

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : Synthon investigational site 203

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : Synthon investigational site 205

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Sofia : Investigational Site Number 5303 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Sofia : Investigational Site Number 5304 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Sofia : Investigational Site Number 5307 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Sofia : Investigational Site Number 5309 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Varna : Synthon investigational site 201

Efficacy and Safety of GTR in Comparison to Copaxone®

Burlington : Central Contact

Canadian Avonex PEN Productivity Study

Burnaby : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Calgary : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Calgary : Investigational Site Number 124005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Calgary : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

View More »

Cambridge : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Chicoutimi : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Edmonton : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Edmonton : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Edmonton : Investigational Site Number 124004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Edmonton : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Edmonton : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Gatineau : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Gatineau : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Gatineau : Investigational Site Number 124003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Gatineau : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Greenfield Park : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Greenfield Park : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Greenfield Park : Investigational Site Number 5402 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Guelp : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Halifax : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Halifax : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Hamlton : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Kingston : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Kingston : Investigational Site Number 124006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

London : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

London : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

London : Investigational Site Number 5403 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Montreal : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Montreal : Investigational Site Number 124007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Montreal : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Montreal : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Montréal : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Ottawa : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Ottawa : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Ottawa : Investigational Site Number 124008 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Ottawa : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Ottawa : Investigational Site Number 5401 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Quebec : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Quebec : Investigational Site Number 5406 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Regina : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Regina : Investigational Site Number 124002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Riviere-Du-Loup : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Saint John : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Saint John : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Saskatoon : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Sherbrooke : Investigational Site Number 124001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Sherbrooke : Investigational Site Number 5408 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

St Johns : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Sydney : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Thunder Bay : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Toronto : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Toronto : Investigational Site Number 5404 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Toronto : Investigational Site Number 5410 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Trois-Rivieres : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Vancouver : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Vancouver : Vancouver Coastal Health: University of British Columbia Hospital

Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis

Vancouver : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Vancouver : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Vancouver : MS Clinic UBC Hospital

Pharmacogenomics of Drug Safety in Multiple Sclerosis

Vancouver : University of British Columbia

Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects

Winnipeg : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Winnipeg : Health Sciences Centre Multiple Sclerosis Clinic

Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis

Winnipeg : Investigational Site Number 124009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Winnipeg : Research Site

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Santiago : Investigational Site Number 152003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Santiago : Investigational Site Number 152004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Santiago : Investigational Site Number 1525601 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Santiago : Investigational Site Number 1525602 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Viña Del Mar : Investigational Site Number 152002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

View More »

Viña Del Mar : Investigational Site Number 152005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Viña Del Mar : Investigational Site Number 1525605 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Many locations :

China Betaferon Adherence, Coping and Nurse Support Study

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Nanjing : Nanjing University Medical College Affiliated Drum Tower Hospital

Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica

Barranquilla : Investigational Site Number 170001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bogota : Investigational Site Number 170005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bogota : Investigational Site Number 170002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bogota : Investigational Site Number 170006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bogota : Investigational Site Number 170007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

View More »

Bucaramanga : Investigational Site Number 170004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Medellin : Investigational Site Number 170009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Varazdin : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Zagreb : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Zagreb : Teva Investigational Site 60001 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Zagreb : Teva Investigational Site 60002 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Zagreb : Teva Investigational Site 60006 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Brno : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Brno : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Brno : Investigational Site Number 5801 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Brno : Research Site

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis

Brno-bohunice : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

View More »

Hradec Kralove : Novartis Investigative Site

A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis

Hradec Kralove : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Hradec Kralove : Research Site

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis

Jihlava : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Jihlava : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Jihlava : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Jihlava : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Olomouc : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Olomouc : Investigational Site Number 5804 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Ostrava : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Ostrava - Poruba : Investigational Site Number 5805 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Pardubice : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Pardubice : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Prague : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Praha : Novartis Investigative Site

A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis

Praha 10 : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Praha 2 : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Praha 2 : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Teplice : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Teplice : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Teplice : Research Site

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis

Aarhus C : Investigational Site Number 208002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Aarhus C : MS Clinic, Department of Neurology, Aarhus University Hospital

Multiple Sclerosis and Progressive Resistance Training

Aarhus C : Sport Science, Aarhus University

Multiple Sclerosis and Progressive Resistance Training

Aarhus C : Investigational Site Number 6002 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Copenhagen : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

View More »

Esbjerg : Research Site

A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis

Esbjerg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Glostrup : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Glostrup : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Glostrup : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

København : Dansk Multipel Sclerose Center

Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis

København Ø : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Koebenhavn Ø : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Odense : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Odense C : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Sønderborg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Vejle : Research Site

A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis

Vejle : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Viborg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Tallinn : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tallinn : Investigational Site Number 233002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Tallinn : Investigational Site Number 6201 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Tallinn : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

View More »

Tartu : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tartu : Investigational Site Number 233001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Tartu : Investigational Site Number 6203 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Helsinki : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Helsinki : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Helsinki : Investigational Site Number 246003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Helsinki : Investigational Site Number 6405 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Helsinki : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

View More »

Helsinski : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Hyvinkää : Investigational Site Number 246006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Jyväskylä : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Jyväskylä : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations : Updated

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Oulu : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Oulu : Investigational Site Number 246004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Pori : Investigational Site Number 246002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Seinäjoki : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tampere : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tampere : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tampere : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Tampere : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tampere : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Turku : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Turku : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Turku : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Turku : Investigational Site Number 246001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Turku : Investigational Site Number 6401 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Turku : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Agen : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Aix En Provence : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Amiens : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Amiens : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Angers : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

View More »

Auxerre : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Avignon : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Bayonne : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Belfort : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Besancon : Investigational Site Number 250003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Besancon : Investigational Site Number 6611 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Beziers : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Bobigny : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Bobigny : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Bordeaux : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bordeaux : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Bordeaux : Service de Neurologie - Pôle des Neurosciences Cliniques, CHU de Bordeaux.

Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis

Boulogne Sur Mer : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Bourdeaux : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Brest : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Bron : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Caen : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Caen Cedex 5 : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Calais : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Castelnau Le Lez : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Chambray Les Tours : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Cherbourg Octeville : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Clermont Ferrand : Hôpital Gabriel Montpied

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Clermont Ferrand Cedex 1 : Investigational Site Number 250010 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Clermont Ferrand Cedex 1 : Investigational Site Number 6601 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Clermont-ferrand : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Clermont-ferrand : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Dijon : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Dijon : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Epinal : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Garches : Hopital Raymond Poincaré

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Grenoble : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Haguenau : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

La Rochelle : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

La Seyne Sur Mer : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Le Kremlin Bicetre : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Le Mans : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Lille : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lille : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Lille : Hôpital Roger Salengro

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Lille Cedex : Investigational Site Number 250005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Lille Cedex : Investigational Site Number 6609 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Limoges : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

L'union : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Lyon : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Lyon : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Lyon Cedex 03 : Investigational Site Number 250002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Marseille : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Marseille : Hopital de la conception

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Marseille : La Timone University Hospital (APHM)

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Marseille Cedex 9 : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Metz : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Montauban : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Montbeliard : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Montpellier : CHU Hôpital Gui de Chauliac Service de Neurologie B

A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly

Montpellier : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Montpellier : Hôpital Guy de Chauliac

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Montpellier Cedex 05 : Investigational Site Number 6604 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Montpellier Cedex 5 : Investigational Site Number 250004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Mulhouse : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Nancy : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Nancy : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Nancy Cedex : Investigational Site Number 250001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Nancy Cedex : Investigational Site Number 6612 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Nantes : CHU Hotel Dieu

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Nantes Cedex 01 : Investigational Site Number 250006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Nantes Cedex 01 : Investigational Site Number 6605 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Nice : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Nice : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Nice Cedex : Investigational Site Number 6602 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Nimes : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Nimes : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Nimes : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Nimes : Investigational Site Number 6614 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Orleans : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Orsay : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Paris : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Paris : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Paris : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Paris : Hopital Tenon

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Paris : La Pitie-Salpaetriere Hospital (APHP)

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Paris Cedex 20 : Investigational Site Number 250007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Paris Cedex 5 : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Pau : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Poissy : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Poitiers : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Pontoise : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Quimper : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Reims : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Reims : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Reims : Maison Blanche Hospital

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Rennes : Rennes University Hospital

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Roanne : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Rouen : CHU Rouen - Hopital Charles Nicolle

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Sainte Foy Les Lyon : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Saumur : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

St Aubin Sur Scie : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Strasbourg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Strasbourg : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Strasbourg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Strasbourg : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Strasbourg : Nouvel Hôpital Civil, Clinique Neurologique

Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis

Strasbourg Cedex : Investigational Site Number 6607 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Talant : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Toulouse : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Toulouse : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Toulouse : CHU Toulouse - Hopital Rangueil

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Toulouse : Purpan Hospital

The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.

Toulouse Cedex 3 : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tourcoing : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Tours : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Vichy : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Tbilisi : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tbilisi : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Aachen : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Achim : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Achim : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Asbach : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Aschaffenburg : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

View More »

Bad Mergentheim : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Bad Mergentheim : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Bad Mergentheim : Investigational Site Number 276009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bad Neustadt / Saale : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Bad Wilbad : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Baesweiler : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bamberg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Bamberg : Investigational Site Number 276020 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bamberg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Bamberg : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Bayreuth : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Bayreuth : Investigational Site Number 276003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bayreuth : Investigational Site Number 6801 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Berg-kemptenhausen : Research Site

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice

Berlin : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Berlin : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Berlin : Novartis Investigative Site

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

Berlin : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Berlin : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Berlin : Investigational Site Number 276015 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Berlin : Investigational Site Number 276016 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Berlin : Investigational Site Number 276021 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Berlin : Investigational Site Number 276007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Berlin : St. Hedwig Hospital, Department of Urology

Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction

Berlin : NeuroCure Clinical Research Center, Charité Berlin

Flupirtine as Oral Treatment in Multiple Sclerosis

Berlin : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Berlin : Morphosys Investigative Site

Phase Ib Study to Evaluate the Safety and Pharmacokinetics of MOR103, a Human Antibody to GM-CSF, in Patients With Multiple Sclerosis

Berlin : Investigational Site Number 6805 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Berlin : Investigational Site Number 6810 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Berlin : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Berlin : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Bielefeld : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Bielefeld : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Böblingen : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Bochum : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Bochum : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Bochum : Novartis Investigative Site

Pregnancy Registry Trial

Bochum : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Bogen : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Bonn : Investigational Site Number 276012 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Butzbach : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Dresden : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Dresden : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Dresden : Investigational Site Number 276005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Dresden : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Dresden : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Düsseldorf : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Düsseldorf : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Düsseldorf : Investigational Site Number 276032 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Düsseldorf : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Erbach : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Erbach : Investigational Site Number 276018 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Erbach : Investigational Site Number 6807 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Erfurt : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Erlangen : Investigational Site Number 276004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Erlangen : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Essen : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Frankfurt : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Frankfurt : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Frankfurt Am Main : Investigational Site Number 276025 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Freiburg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Freiburg : Investigational Site Number 276028 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Freiburg : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Freiburg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

GIEßEN : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Gießen : Investigational Site Number 276006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Göttingen : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Göttingen : University of Göttingen, Department of Neurology

Flupirtine as Oral Treatment in Multiple Sclerosis

Hamburg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Hamburg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Hamburg : Investigational Site Number 276010 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Hamburg : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Hamburg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Hannover : Investigational Site Number 6809 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Hannover : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Heidelberg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Heidelberg : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Hennigsdorf : Investigational Site Number 276022 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Ingolstadt : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Jena : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Jena : Univeristaetsklinikum Jena

Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis

Kandel : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Kassel : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Kassel : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Kassel : Investigational Site Number 276024 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Kassel : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Koeln : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Köln : Investigational Site Number 6813 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Köln : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Leipzig : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Leipzig : Investigational Site Number 276001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Leipzig : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Leverkusen : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Ludwigshafen : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Ludwigshafen : Investigational Site Number 6804 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Mainz : Investigational Site Number 276013 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Many Locations : Updated

Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

Many Locations :

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Many Locations : Updated

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Marburg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Marburg : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Minden : Investigational Site Number 276023 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Minden : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Muenchen : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Muenster : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

München : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

München : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Munich : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Munster : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Münster : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Münster : Investigational Site Number 276002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Münster : Investigational Site Number 6802 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Münster : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Oldenburg : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Osnabrück : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Prien : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Regensburg : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Regensburg : Investigational Site Number 6814 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Regensburg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Rostock : Investigational Site Number 276031 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Rostock : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Siegen : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Siegen : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Stuttgart : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Stuttgart : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Teupitz : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tübingen : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tübingen : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Tübingen : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tuebingen : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

ULM : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

ULM : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Ulm : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Ulm : University of Ulm, Department of Neurology

Flupirtine as Oral Treatment in Multiple Sclerosis

Ulm : Investigational Site Number 6812 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Wermsdorf : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Wermsdorf : Investigational Site Number 276014 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Westerstede : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Wiesbaden : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Wiesbaden : Investigational Site Number 276008 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Wiesbaden : Investigational Site Number 6806 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Wuppertal : Investigational Site Number 276026 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Würzburg : Investigational Site Number 276011 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Athens : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Athens : Henry Dunant Hospital - IRB

An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters

Athens : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Athens : Investigational Site Number 300001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Athens : Investigational Site Number 300002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

View More »

Heraklion : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Heraklion : Investigational Site Number 300003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Ioannina : Investigational Site Number 300004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Larissa : Investigational Site Number 300005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Thessaloniki : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Thessaloniki : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Thessaloniki : Investigational Site Number 300006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Budapest : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Budapest : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Budapest : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Budapest : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Budapest : Investigational Site Number 348006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

View More »

Budapest : Investigational Site Number 348010 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Budapest : Investigational Site Number 348002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Budapest : Investigational Site Number 7101 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Budapest : Investigational Site Number 7103 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Budapest : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Debrecen : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Eger : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Eger : Investigational Site Number 348009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Esztergom : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Esztergom : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Esztergom : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Esztergom : Investigational Site Number 348003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Gyor : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Kaposvár : Investigational Site Number 348008 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Miskolc : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Nyiregyhaza : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Nyíregyháza : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Pécs : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Pécs : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Szeged : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Szeged : Investigational Site Number 348001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Szeged : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Szekesfehervar : Investigational Site Number 348005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Székesfehérvár : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Veszprem : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Veszprém : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Veszprém : Investigational Site Number 348011 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Veszprém : Investigational Site Number 7105 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Zalaegerszeg : Investigational Site Number 348007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bangalore : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Delhi : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Hyderabad : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Mumbai : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Nagpur : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

View More »

New Delhi : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Trivandrum : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Dublin : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Ashkelon : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Ashkelon : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Haifa : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Kfar Saba : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

View More »

Petach Tikva : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Petach Tikva : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Ramat-gan : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Safed : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Tzfat : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tzrifin : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Ancona : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Ancona : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Bari : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Barletta : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Bergamo : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

View More »

Bolzano : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Cagliari : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Cagliari : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Cagliari : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Caltanissetta : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Catania : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Catania : Investigational Site Number 380009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Catania : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Catania : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Catanzaro : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Cefalu : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Cefalù : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Cefalù : Investigational Site Number 380002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Cefalù : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Chieti : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Como : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Cuneo : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Empoli : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Fidenza : Investigational Site Number 380003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Fidenza : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Firenze : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Firenze : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Foggia : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Gallarate : Investigational Site Number 380004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Gallarate : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Genova : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Genova : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Genova : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Genova : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Imperia : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

L'Aquila : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Lecce : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Legnago : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Merano : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Messina : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Messina : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Milan : Institute of Experimental Neurology

Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity

Milano : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Milano : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Milano : Investigational Site Number 380001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Milano : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Milano : Novartis Investigational Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Milano : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Milano : Ospedale San Raffaele

Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis

Modena : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Montichiari : Investigational Site Number 380012 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Napoli : Investigational Site Number 380011 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Napoli : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Napoli : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Novara : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Orbassano : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Orbassano : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Orbassano : Investigational Site Number 380007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Padova : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Padova : Investigational Site Number 380006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Padova : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Palermo : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Pavia : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Pavia : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Perugia : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Pisa : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Reggio Calabria : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Roma : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Roma : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Roma : Investigational Site Number 380008 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Roma : Investigational Site Number 380005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Roma : Novartis Investigative Site

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Rome : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

San Donato Milanese : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Trieste : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Verona : Investigational Site Number 380014 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Verona : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Chiba, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Chiba, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Fukuoka, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Fukuoka, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Hiroshima, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

View More »

Hiroshima, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Kawagoe, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Kawagoe, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Kodaira, : University of British Columbia

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Kodaira, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Kyoto, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Kyoto, : London Health Sciences Centre

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Kyoto, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Morioka, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Morioka, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Niigata, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Niigata, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Osaka, : Univ of Calgary / Foothills MC

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Osaka, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Osaka, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Sapporo, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sapporo, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Sendai, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sendai, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Suita, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Suita, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Tokorozawa, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Tokorozawa, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Tokyo, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Tokyo, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Tsukuba, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Tsukuba, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Ube, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Ube, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Yokohama, : Research Site

BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Yokohama, : Research Site

Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Goyang-Si : Investigational Site Number 410002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Many Locations :

Betaferon® Regulatory Post-Marketing Surveillance

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Seoul : Investigational Site Number 410001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Seoul : Investigational Site Number 410003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

View More »

Seoul : Investigational Site Number 410004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Seoul : Investigational Site Number 410005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Riga : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Riga : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Kaunas : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Kaunas : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Kaunas : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Klaipeda : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Klaipeda : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

View More »

Klaipeda : Investigational Site Number 7402 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Siauliai : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Siauliai : Investigational Site Number 7403 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Vilnius : Investigational Site Number 7401 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Kuala Lumpur : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Penang : Novartis Investigative Site

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Aguascalientes : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Aguascalientes : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Chihuahua : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Guadalajara : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

View More »

Mexico : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Mexico : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tijuana : Hospital Angeles

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis

Chisinau : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Amsterdam : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Amsterdam : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Breda : Investigational Site Number 528001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Breda : Amphia Ziekenhuis

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)

Breda : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

View More »

Eindhoven : Investigational Site Number 528003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Eindhoven : Research Site

Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis

Eindhoven : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Gouda : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Leeuwarden : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Nieuwegein : Investigational Site Number 528005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Nieuwegein : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Nijmegen : UMC ST Radboud Nijmegen, Department of Urology

Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction

Sittard : Research Site

An Observational Study to Assess Persistence, Adherence, Quality of Life, and Treatment Satisfaction in Patients Beginning Therapy With the Avonex® PEN™

Sittard : Maasland Ziekenhuis

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)

Sittard : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Sittard-Geleen : Investigational Site Number 528002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Venray : Investigational Site Number 528006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Venray : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Christchurch : Primorus Clinical Trials, 40 Stewart Street

Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis

Hamilton : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Bergen : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Lørenskog : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Molde : Molde Hospital

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice

Oslo : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

View More »

Oslo : Investigational Site Number 578001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Oslo : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Sandvika : Sandvika Nevrosenter

A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects

Tønsberg : Investigational Site Number 578002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bellavista : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lima : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Bialystok : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Bialystok : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Bialystok : Research Site

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis

Bydgoszcz : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bydgoszczas : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

View More »

Czestochowa : Teva Investigational Site 53020 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Gdansk : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Gdansk : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Gdansk : Investigational Site Number 7709 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Gdansk : Research Site

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis

Grudziadz : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Katowice : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Katowice : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Katowice : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Katowice : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Katowice : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Katowice : Teva Investigational Site 53021 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Kielce : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Kielce : Teva Investigational Site 53019 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Konskie : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Krakow : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Krakow : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Krakow : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Krakow : Research Site

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis

Kraków : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Lodz : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Lodz : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lodz : Investigational Site Number 7710 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Lodz : Research Site

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis

Lodz : Coordinating Research Site

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis

Lodz : Teva Investigational Site 53018 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Lódz : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Lublin : Medical University, Department of Neurology

An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)

Lublin : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Lublin : Research Site

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis

Many Locations : Updated

Depression and Fatigue in MS Patients Treated With Betaferon.

Olsztyn : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Olsztyn : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Plewiska : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Poznan : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Poznan : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Poznan : Morphosys Investigative Site

Phase Ib Study to Evaluate the Safety and Pharmacokinetics of MOR103, a Human Antibody to GM-CSF, in Patients With Multiple Sclerosis

Poznan / Plewiska : Teva Investigational Site 53030 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Szczecin : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Szczecin : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Szczecin : Teva Investigational Site 53026 Updated

To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Warszawa : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Warszawa : Investigational Site Number 7701 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Warszawa : Investigational Site Number 7703 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Warszawa 44 : Investigational Site Number 7707 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Amadora : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Amadora : Investigational Site Number 620001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Coimbra : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Coimbra : Investigational Site Number 620004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Coimbra : Centro Hospitalar de Coimbra, EPE

Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis

View More »

Lisboa : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lisbon : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Porto : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Setubal : Investigational Site Number 620003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Guaynabo : Caribbean Center for Clinical Research, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Bucharest : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Bucurest : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Bucuresti : Investigational Site Number 7803 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Bucuresti : Investigational Site Number 7806 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Cluj-Napoca : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

View More »

Cluj-Napoca : Investigational Site Number 7805 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Cluj-Napoca : Investigational Site Number 7807 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Iasi : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Târgu Mures : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Timisoara : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Timisoara : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Timisoara : Investigational Site Number 7808 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Belgorod : Novartis Investigative Site

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Chelyabinsk : Municipal Healthcare Institution "City Clinical Hospital #3", Department of neurology

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

Chelyabinsk : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Ekaterinburg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Kaluga : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

View More »

Kaluga : Investigational Site Number 643012 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Kazan : State Medical Institution "Republican Clinical Hospital of rehabilitation treatment of Ministry of Healthcare of Tatarstan Republic", Republican clinicodiagnostic center of demyelinating diseases of Ministry of Healthcare of Tatarstan Republic

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

Kazan : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Kazan : Investigational Site Number 643007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Kazan : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Kazan : Investigational Site Number 7907 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Kemerovo : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Kemerovo : Investigational Site Number 643001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Krasnoyarsk : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Moscow : State Educational Institution of Higher Professional Education "1st Moscow State Medical University n.a. I.M. Sechenov of Ministry of Healthcare and Social Development of the Russian Federation, Department of new drugs research

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

Moscow : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Moscow : Investigational Site Number 643013 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Moscow : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

N. Novgorod : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Nizhny Novgorod : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Nizhny Novgorod : Investigational Site Number 643006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Nizhny Novgorod : Investigational Site Number 643004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Nizhny Novgorod : Investigational Site Number 7909 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Nizhny Novgorod : Investigational Site Number 7904 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Nizhny Novgorod : Investigational Site Number 7906 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Novosibirsk : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Novosibirsk : Investigational Site Number 643015 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Novosibirsk : Investigational Site Number 7912 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Perm : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Rostov-on-Don : State Healthcare Institution 'Rostov Regional Clinical Hospital' Center of Neurology

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

Rostov-on-Don : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Rostov-On-Don : Investigational Site Number 643009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Rostov-On-Don : Investigational Site Number 643010 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Saint Petersburg : State Educational Institution of Higher Professional Education "St. Petersburg State Medical University n.a. I.V. Pavlov of Roszdrav", Department of neurology with clinic

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

Saint Petersburg : LLC "International Clinic MEDEM", Department of functional diagnostics

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

Saint Petersburg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Samara : State Healthcare Institution "Samara Regional Clinical Hospital n.a. M.I. Kalinin", Department of neurosurgery

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

Samara : Investigational Site Number 643016 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Saratov : State Educational Institution of Higher Professional Education Saratov State Medical University

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

Smolensk : State Educational Institution of Higher Professional Education "Smolensk State Medical Academy of Roszdrav", Department of neurology and neurosurgery based at State Healthcare Institution "Smolensk Regional Clinical Hospital"

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

Smolensk : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Smolensk : Investigational Site Number 643005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Smolensk : Investigational Site Number 7905 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

St Petersburg : St. Petersburg State Healthcare Institution "City multifield hospital #2", Department of neurology #2

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

St Petersburg : Institution of the Russian Academy of Science "Institute of Human Brain of RAS", Neuroimmunology Laboratory

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

St.Petersburg : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

St-Petersburg : Investigational Site Number 643017 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

St-Petersburg : Investigational Site Number 643003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

St-Petersburg : Investigational Site Number 643011 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

St-Petersburg : Investigational Site Number 643018 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

St-Petersburg : Investigational Site Number 643002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

St-Petersburg : Investigational Site Number 7911 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Tomsk : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tumen : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Ufa : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Yaroslavl : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Yaroslavl : Investigational Site Number 643014 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Belgrade : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Kragujevac : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Nis : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Novi Sad : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Banska Bystrica : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Bratislava : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Martin : Investigational Site Number 703002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Trnava : Investigational Site Number 703001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Ljubljana : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Alicante : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Alicante : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Badalona : Hospital Germans Trias i Pujol

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Barcelona : Hospital Clinic i Provincial

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Barcelona : Hospital Vall d'Hebrón

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

View More »

Barcelona : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Barcelona : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Barcelona : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Barcelona : Investigational Site Number 724001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Barcelona : Investigational Site Number 724002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Barcelona : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Bilbao : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Bilbao : Investigational Site Number 724006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Castellón : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Cordoba : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Córdoba : Investigational Site Number 724009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Girona : Hospital Universitari Josep Trueta

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Girona : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Girona : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Girona : Investigational Site Number 724003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Girona : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

L´Hospitalet de Llobregat : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Madrid : Hospital Universitario La Paz

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Madrid : Hospital Universitario Puerta del Hierro

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Madrid : Hospital Clínico San Carlos

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Madrid : Hospital Universitario La Princesa

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Madrid : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Madrid : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Madrid : Investigational Site Number 724004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Madrid : Investigational Site Number 724005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Malaga : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Malaga : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Málaga : Hospital Regional Universitario Carlos Haya

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Murcia : Investigational Site Number 724007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Santiago de Compostela : Complexo Hospitalario Universitario de Santiago

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Sevilla : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Sevilla : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Sevilla : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Sevilla : Investigational Site Number 724008 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Sevilla : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Valencia : Hospital Universitario La Fe

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Eskilstuna : Investigational Site Number 752002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Göteborg : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Göteborg : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Göteborg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Göteborg : Investigational Site Number 752004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

View More »

Linköping : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Malmö : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Örebro : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Stockholm : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Stockholm : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Stockholm : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Stockholm : Investigational Site Number 752001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Stockholm : Investigational Site Number 752003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Umeå : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Umeå : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Basel : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Basel : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Bern : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Lausanne : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Lugano : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

View More »

Lugano : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Lugano : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

St. Gallen : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Zug : Biogen Idec International GmbH, Global Medical Affairs

TOP: IMA-06-02 Tysabri Observational Program

Zurich : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Manouba : Investigational Site Number 788002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Monastir : Investigational Site Number 788005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Sfax : Investigational Site Number 788004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Tunis : Investigational Site Number 788006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

?stanbul : Investigational Site Number 8310 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Edirne : Investigational Site Number 8304 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Istanbul : Investigational Site Number 8309 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Istanbul : Investigational Site Number 8312 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Istanbul : Investigational Site Number 8308 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

View More »

Izmir : Investigational Site Number 8305 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Izmir : Investigational Site Number 8303 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Izmir : Investigational Site Number 8301 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Izmit : Investigational Site Number 8302 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Trabzon : Investigational Site Number 8314 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Chernihiv : Investigational Site Number 8507 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Chernivtsi : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Dnepropetrovsk : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Dnipropetrovsk : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Dnipropetrovsk : Investigational Site Number 8501 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

View More »

Donetsk : Investigational Site Number 8511 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Kharkiv : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Kharkiv : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Kharkiv : Investigational Site Number 8506 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Kharkov : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Kharkov : Investigational Site Number 8504 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Kiev : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Kiev : Investigational Site Number 8508 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Kyiv : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Kyviv : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Lutsk : Investigational Site Number 8512 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Lviv : Investigational Site Number 8505 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Odesa : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Odessa : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Poltava : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Poltava : Investigational Site Number 8510 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Vinnitsa : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Vinnytsya : Investigational Site Number 8503 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Zaporozhye : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Zaporozhye : Investigational Site Number 8502 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Birmingham : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Birmingham : Investigational Site Number 826008 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Brighton : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Brighton : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Bristol : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

View More »

Devon : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Edinburgh : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Leeds : Investigational Site Number 826005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Liverpool : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Liverpool : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Liverpool : Investigational Site Number 826006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Liverpool : Investigational Site Number 8709 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

London : GSK Investigational Site

[18F]PBR111 and Microglial Activation in Multiple Sclerosis

London : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

London : National Hospital for Neurology & Neurosurgery

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

London : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

London : Investigational Site Number 826003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

London : University College of London, Institute of Neurology

Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction

London : Imperial College NHS Trust

Patient Research Cohort: Rapidly Evolving Multiple Sclerosis

London : Investigational Site Number 8704 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

London : Investigational Site Number 8701 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Manchester : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Manchester : Morhosys Investigative Site

Phase Ib Study to Evaluate the Safety and Pharmacokinetics of MOR103, a Human Antibody to GM-CSF, in Patients With Multiple Sclerosis

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations : Updated

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Merck KGaA Communication Center for recruiting locations : Please conatact the Updated New

The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

Morriston : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

New Castle Upon Tyne : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Nottingham : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Nottingham : Updated

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Nottingham : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Nottingham : Investigational Site Number 8705 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Nottingham : Research Site

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis

Plymouth : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Plymouth : Investigational Site Number 826004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Plymouth : Investigational Site Number 8708 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Plymouth : Research Site

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis

Salford : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Salford : Investigational Site Number 826001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Salford : Investigational Site Number 8707 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Sheffield : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Sheffield : Royal Hallamshire Hospital

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

Sheffield : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Sheffield : Royal Hallamshire Hospitals NHS Trust

Open-Label Study to Assess the Effect of Fampridine-PR on Quality of Life as Reported by Subjects With Multiple Sclerosis

Sheffield : Investigational Site Number 8702 Updated

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Stoke on Trent : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Swansea : Research Site

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Swansea : Updated

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

DC : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Washington : Research Site

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment